Abstract
Background Postpartum psychosis, a mood disorder triggered by childbirth, is one of the most severe psychiatric conditions, with high risks of suicide and infanticide if untreated. While it is evident that genetic factors play a crucial role in disorder risk, the exact extent of their importance is yet to be determined.
Methods This cohort study consisted of 1,633,535 birthing parents from the Swedish nationwide registers, of whom 2,489 (0·15%) experienced postpartum psychosis within three months of their first ever childbirth. We estimated the relative recurrence risk of postpartum psychosis for full siblings and cousins as a measure of familial, genetic, and environmental risk.
Findings Relative recurrence risk of postpartum psychosis in full siblings was 13·77 (95% CI 8·52-20·91) when adjusted for age at birth. Although cousins showed an elevated relative recurrence risk, these results did not reach statistical significance (1·88 [95% CI 0·74-3·82]). In full siblings, the relative recurrence risk for severe postpartum psychosis requiring inpatient diagnosis was even higher than the risk for inpatient and outpatient diagnoses (18·13 [95% CI 11·12-27·57]).
Interpretation Increased risk of postpartum psychosis in full siblings is likely due to a combination of genetic factors and shared environment. The elevated risk in cousin pairs, lower than in full siblings, highlights genetic impact because shared environmental effects are assumed to be minimal among cousins. However, caution is needed in interpreting the risk among cousins due to wide confidence intervals. Overall, our study supports the role of genetics and shared environment in the risk of postpartum psychosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant from the Beatrice and Samuel A. Seaver Foundation (BM); and the National Institute of Mental Health (NIMH), R21MH131933 (VB, KH, APK, BM, TMO, TKR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval and waiver of informed consent (which is not required for the use of register data) were obtained from the Regional Ethical Review Board in Stockholm, Sweden
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Shared authors
Data Availability
Data may be obtained from a third party and are not publicly available. Data cannot be shared publicly owing to restrictions by law. Data are available from the National Medical Registries in Sweden after approval by the Swedish Ethical Review Authority.
